Linked Life Data

20463006

Source:http://linkedlifedata.com/resource/pubmed/id/20463006

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20463006rdf:typepubmed:Citationlld:pubmed
pubmed-article:20463006lifeskim:mentionsumls-concept:C0023418lld:lifeskim
pubmed-article:20463006lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:20463006lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:20463006lifeskim:mentionsumls-concept:C0031715lld:lifeskim
pubmed-article:20463006lifeskim:mentionsumls-concept:C0600531lld:lifeskim
pubmed-article:20463006lifeskim:mentionsumls-concept:C0243045lld:lifeskim
pubmed-article:20463006lifeskim:mentionsumls-concept:C0041348lld:lifeskim
pubmed-article:20463006lifeskim:mentionsumls-concept:C0376515lld:lifeskim
pubmed-article:20463006lifeskim:mentionsumls-concept:C0314672lld:lifeskim
pubmed-article:20463006lifeskim:mentionsumls-concept:C1444748lld:lifeskim
pubmed-article:20463006lifeskim:mentionsumls-concept:C0237477lld:lifeskim
pubmed-article:20463006lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:20463006lifeskim:mentionsumls-concept:C1513354lld:lifeskim
pubmed-article:20463006pubmed:issue2lld:pubmed
pubmed-article:20463006pubmed:dateCreated2010-7-19lld:pubmed
pubmed-article:20463006pubmed:abstractTextWe investigated the signaling pathways associated with microtubule interaction and apoptosis in U937 cells in vitro and in the U937 xenograft model in vivo by using 6-pyrrolidinyl-2-(2-hydroxyphenyl)-4-quinazolinone (MJ-29). MJ-29 induced growth inhibition and cell death of leukemia cell lines (U937, HL-60, K562, and KG-1) in a dose- and time-dependent manner but did not obviously impair the viability of normal cells (peripheral blood mononuclear cells and human umbilical vein endothelial cells). MJ-29 interacted with alpha- and beta-tubulin, inhibited tubulin polymerization both in vitro and in vivo, and disrupted microtubule organization. MJ-29 caused mitotic arrest by activating cyclin-dependent kinase 1 (CDK1)/cyclin B complex activity. MJ-29-induced growth inhibition and activation of CDK1 activity were significantly attenuated by roscovitine (CDK inhibitor) and CDK1 small interfering RNA (siRNA). Furthermore, MJ-29-induced Bcl-2 phosphorylation was also significantly attenuated by CDK1 siRNA. MJ-29 caused an increase in the protein levels of cytosolic cytochrome c, apoptotic protease-activating factor-1, procaspase-9, and apoptosis-inducing factor. MJ-29-promoted activation of caspase-9 and caspase-3 during apoptosis was significantly attenuated by caspase-9 and caspase-3 inhibitors. It is noteworthy that in BALB/c(nu/nu) mice bearing U937 xenograft tumors MJ-29 inhibited tumor growth in vivo. The terminal deoxynucleotidyl transferase-mediated d-UTP nick end-labeling-positive apoptotic cells of tumor sections significantly increased in MJ-29-treated mice compared with the control group. In conclusion, our results suggest that MJ-29 induces mitotic arrest and apoptosis in U937 cells via CDK1-mediated Bcl-2 phosphorylation and inhibits the in vivo tumor growth of U937 xenograft mice.lld:pubmed
pubmed-article:20463006pubmed:languageenglld:pubmed
pubmed-article:20463006pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20463006pubmed:citationSubsetIMlld:pubmed
pubmed-article:20463006pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20463006pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20463006pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20463006pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20463006pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20463006pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20463006pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20463006pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20463006pubmed:statusMEDLINElld:pubmed
pubmed-article:20463006pubmed:monthAuglld:pubmed
pubmed-article:20463006pubmed:issn1521-0103lld:pubmed
pubmed-article:20463006pubmed:authorpubmed-author:ChungJing-Gun...lld:pubmed
pubmed-article:20463006pubmed:authorpubmed-author:KuoSheng-ChuS...lld:pubmed
pubmed-article:20463006pubmed:authorpubmed-author:YangJai-SingJ...lld:pubmed
pubmed-article:20463006pubmed:authorpubmed-author:HourMann-JenM...lld:pubmed
pubmed-article:20463006pubmed:authorpubmed-author:HuangWen-WenW...lld:pubmed
pubmed-article:20463006pubmed:authorpubmed-author:LinKuei-LiKLlld:pubmed
pubmed-article:20463006pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20463006pubmed:volume334lld:pubmed
pubmed-article:20463006pubmed:ownerNLMlld:pubmed
pubmed-article:20463006pubmed:authorsCompleteYlld:pubmed
pubmed-article:20463006pubmed:pagination477-88lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:meshHeadingpubmed-meshheading:20463006...lld:pubmed
pubmed-article:20463006pubmed:year2010lld:pubmed
pubmed-article:20463006pubmed:articleTitleMJ-29 inhibits tubulin polymerization, induces mitotic arrest, and triggers apoptosis via cyclin-dependent kinase 1-mediated Bcl-2 phosphorylation in human leukemia U937 cells.lld:pubmed
pubmed-article:20463006pubmed:affiliationDepartment of Pharmacology, China Medical University, Taichung, Taiwan.lld:pubmed
pubmed-article:20463006pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20463006pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20463006lld:pubmed